Fintel reports that on March 21, 2025, Goldman Sachs initiated coverage of Sanofi - Depositary Receipt () (NasdaqGS:SNY) with a Neutral recommendation. As of March 19, 2025, the average one-year ...

The Goldman Sachs Group started coverage on shares of Sanofi (NASDAQ:SNY – Free Report) in a research report sent to investors on Friday morning, Marketbeat Ratings reports. The firm issued a neutral ...

Sanofi (NASDAQ:SNY) said on Tuesday that the US FDA has granted priority review to the regulatory submission of tolebrutinib ...

Below is Validea's guru fundamental report for SANOFI SA (ADR) (SNY). Of the 22 guru strategies we follow, SNY rates highest using our Acquirer's Multiple Investor model based on the published ...

Under the terms of the merger agreement, Sanofi will acquire DR-0201 through the acquisition of the Dren Bio affiliate ...

Saint Gobain, Sanofi and L'Oreal are up 1 to 1.2% ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New ...

Sanofi (NASDAQ:SNY) has struck a major deal to acquire Dren Bios autoimmune disease treatment, DR-0201, reinforcing its ...

HighTower Advisors LLC increased its position in shares of Sanofi (NASDAQ:SNY – Free Report) by 3.4% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The ...

Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis If approved, tolebrutinib would be the first and only brain-penetrant BTK inhibitor to ...

Aide mémoire Paris, France - March 24, 2025. Sanofi announced today that its Q1 2025 Aide mémoire is available on the "Investors" page of the company's website: First ...

Madness: Watch DraftKings, FanDuel, Robinhood, and Grand Canyon. CoreWeave seeks shares ranging from $47 to $55 in IPO:report ...